SEC Company Response from vTv Therapeutics (VTVT) — Jun 9, 2021
vTv Therapeutics Inc.
Date: June 9, 2021 · CIK: 0001641489 · Accession: 0000950142-21-001882
AI Filing Summary & Sentiment
File numbers found in text: 333-256755
Letter
VIA EDGAR Division of Corporation Finance Securities and Exchange Commission Attention: Fredrick Philantrope vTv Therapeutics Inc. Registration Statement on Form S-3 (File No. 333-256755)
Dear Mr. Philantrope:
Pursuant to Rule 461 of the Securities Act of 1933, as amended, we hereby request that the effective date of the above-captioned Registration Statement on Form S-3 of vTv Therapeutics Inc. (the “Company”), be accelerated to June 11, 2021 at 4:00 p.m. Eastern Time or as soon thereafter as may be practicable.
We understand that the Staff will consider this request as confirmation by the Company of its awareness of its responsibilities under the federal securities laws as they relate to the issuance of the securities covered by the Registration Statement. If you have any questions regarding the foregoing, please contact Raphael M. Russo of Paul, Weiss, Rifkind, Wharton & Garrison LLP at (212) 373-3309.
*****
Very truly yours,
vTv Therapeutics
inc.
Show Raw Text
CORRESP
1
filename1.htm
vTv Therapeutics Inc.
3980 Premier Drive
Suite 310
High Point, NC 27265
June 9, 2021
VIA EDGAR
Division of Corporation Finance
Securities and Exchange Commission
100 F Street, N.E.
Washington, D.C. 20549
Attention: Fredrick Philantrope
vTv Therapeutics Inc.
Registration Statement on
Form S-3 (File No. 333-256755)
Dear Mr. Philantrope:
Pursuant to Rule
461 of the Securities Act of 1933, as amended, we hereby request that the effective date of the above-captioned Registration Statement
on Form S-3 of vTv Therapeutics Inc. (the “Company”), be accelerated to June 11, 2021 at 4:00 p.m. Eastern Time or as soon
thereafter as may be practicable.
We understand that the Staff will consider
this request as confirmation by the Company of its awareness of its responsibilities under the federal securities laws as they relate
to the issuance of the securities covered by the Registration Statement. If you have any questions regarding the foregoing, please contact
Raphael M. Russo of Paul, Weiss, Rifkind, Wharton & Garrison LLP at
(212) 373-3309.
*****
Very truly yours,
vTv Therapeutics
inc.
By:
/s/ Rudy Howard
Name:
Rudy Howard
Title:
Chief Financial Officer
[Signature Page to Company Acceleration Request]